| 摘要 |
<p>The present invention relates to novel means for prevention and treatment of diseases which are caused by or associated with elevated levels of deoxy- sphingolipids, in particular diabetes (type 1 and type 2 diabetes), particularly diabetic neuropathy, neurodegenerative diseases such as hereditary and sensory neuropathy type I (HSAN1), amyotrophic lateral sclerosis (ALS), Alzheimer disease, other neurological disorders (e.g. depressive disorders, schizophrenia), medication- induced neuriopathies (e.g. induced by treatment with cytostatics like paclitaxel, cisplatin compounds etc.) and other metabolic disorders such as glycogen storage disease type 1a and asthma. Specifically, the invention relates to a pharmaceutical suppression of cytotoxic sphingolipid metabolites, in particular deoxy-sphingolipids to prevent and treat these diseases.</p> |
